GTC Biotherapeutics (fka GTCB)

[keitern]

mblimon, look at a company like, well you pick one of the many small bio techs that are selling for 1/2 of cash in the treasuries, sometimes less. Some of these companies have relatively intact pipelines too. So GTC, with virtually no cash and no revenues yet is valued at roughly 90 million. It still sucks, but you need look no further than this market for micro cap drug development companies to draw the conclusion that GTC management is victim to this environment just like many others.